US industry vows to keep fighting Japanese price move
This article was originally published in Clinica
Executive Summary
US exporters stand to lose a $500 million-annual market and local healthcare will suffer if Japan proceeds with the introduction of foreign reference pricing for medical devices, as planned. That is the view of AdvaMed, the US Advanced Medical Technology Association, which last week said it would actively seek to steer Japan away from its reference pricing initiative via bilateral talks. If it fails, the US may pursue its complaint through the offices of the World Trade Organization, AdvaMed's Jeff Ezell and Ed Rozynski explained during a telephone briefing.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.